{
    "nctId": "NCT00182793",
    "briefTitle": "Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer",
    "officialTitle": "Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) \u00b1 Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "5-Year Relapse-free Survival Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer, meeting 1 of the following stage criteria:\n\n  * Stage IIIB or IIIC disease, meeting both of the following criteria:\n\n    * Must have received prior neoadjuvant or adjuvant therapy\n    * Must have undergone lumpectomy or mastectomy\n  * Stage IV disease, meeting all of the following criteria:\n\n    * Only 1-3 organ sites with disease involvement after induction chemotherapy\n    * Achieved at least a partial response after induction chemotherapy\n    * No more than 3 lesions in the organ sites combined\n* Inflammatory breast cancer allowed\n* Completed chemotherapy, surgery, or radiotherapy for breast cancer within the past 6 months\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 65 and under\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 80-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* SGOT or SGPT \u2264 2 times upper limit of normal\n* Bilirubin \u2264 1.5 mg/dL\n\nRenal\n\n* Creatinine \u2264 1.2 mg/dL\n* Creatinine clearance \u2265 70 mL/min\n\nCardiovascular\n\n* LVEF \u2265 55% by MUGA or echocardiogram\n\nPulmonary\n\n* FEV_1 \u2265 60% of predicted\n* DLCO \u2265 60% of the lower limit of predicted value\n* Oxygen saturation \\> 92% on room air\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No autoimmune disorders\n* No immunosuppressive condition\n* No other malignancy within the past 5 years\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior biologic therapy except trastuzumab (Herceptin\u00ae)\n\nChemotherapy\n\n* See Disease Characteristics\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* See Disease Characteristics\n* No prior radiotherapy to adjacent or involved sites of disease that would preclude study radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* No other concurrent anticancer therapy",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}